Your browser doesn't support javascript.
loading
Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial.
Hilmi, Marc; Kamal, Maud; Vacher, Sophie; Dupain, Célia; Ibadioune, Sabrina; Halladjian, Maral; Sablin, Marie Paule; Marret, Grégoire; Ajgal, Zahra Castel; Nijnikoff, Michèle; Salomon, Anne; El Beaino, Zakhia; Servant, Nicolas; Dureau, Sylvain; Sokol, Harry; Nicolle, Remy; Le Tourneau, Christophe; Bieche, Ivan; Neuzillet, Cindy.
Afiliación
  • Hilmi M; Molecular Oncology, PSL Research University, CNRS, UMR 144, Institut Curie, Paris 75005, France; Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France; Medical Oncology Department, Institut Curie, Saint-Cloud 92210, France. Electronic address: marc.hilmi@curie.fr.
  • Kamal M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France.
  • Vacher S; Department of Genetics, Institut Curie, PSL Research University, Paris 75005, France.
  • Dupain C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France.
  • Ibadioune S; Department of Genetics, Institut Curie, PSL Research University, Paris 75005, France.
  • Halladjian M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France.
  • Sablin MP; Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France.
  • Marret G; Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France.
  • Ajgal ZC; Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France.
  • Nijnikoff M; Institut Curie, PSL Research University, Biological Resource Center, Paris 75248, France.
  • Salomon A; Pathology Department, Institut Curie, 75005 Paris, France.
  • El Beaino Z; Pathology Department, Hopital Tenon, 75020 Paris, France.
  • Servant N; INSERM U900, Mines Paris Tech, Institut Curie, Paris 75000, France.
  • Dureau S; Statistics Department, Institut Curie, Saint-Cloud 92210, France.
  • Sokol H; Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France; Sorbonne University, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, Paris 75012, France; INRA, UMR1319 Micalis & AgroParisTech, Jouy en Josas, Fr
  • Nicolle R; Université Paris Cité, Centre de Recherche sur L'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, Paris F-75018, France.
  • Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris-Saclay University, Paris, France.
  • Bieche I; Department of Genetics, Institut Curie, PSL Research University, Paris 75005, France; INSERM U1016, Faculty of Pharmaceutical and Biological Sciences, Paris Cité University, Paris, France.
  • Neuzillet C; Molecular Oncology, PSL Research University, CNRS, UMR 144, Institut Curie, Paris 75005, France; Paris Center for Microbiome Medicine, Fédération Hospitalo-Universitaire, Paris, France; Medical Oncology Department, Institut Curie, Saint-Cloud 92210, France.
Eur J Cancer ; 183: 152-161, 2023 04.
Article en En | MEDLINE | ID: mdl-36868056
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Antígeno B7-H1 / Microbiota Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Antígeno B7-H1 / Microbiota Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article